APMD net income rises to $193.7M in H1 2026
APMD reported net income of $193.7M for the first half of 2026, driven by SASS divestiture gains. R&D expenses fell as Phase 3 trials for Oxnimbi concluded. Cash was $172.8M pre-IPO and $200.4M raised in August.